Human Monoclonal Antibodies against Cancer-Related Proteins

TEDCO/NIH/NCI Technology Showcase

Dimiter S. Dimitrov

September 25, 2007

Technology Why Human Monoclonal Antibodies?

- Evolved to fight diseases in human bodies
- Their epitopes – vaccine immunogens and targets for inhibitors
- Can be engineered to further increase efficacy



Technology How to Identify Human Monoclonal Antibodies? Antibody Libraries Displayed on Phage



Technology Applications

- Large human antibody libraries containing 10 billion antibodies
- Used for selection of antibodies against cancer-related proteins
- Treatment and diagnosis of cancer

Commercial Applications

- Development of antibody-based cancer therapeutics
- Proteins targeted: IGF-I, IGF-II, IGF-IR, DR4, DR5, Mesothelin, CD22, Her2, EphrinB2
- Viruses targeted: HIV, Hendra virus, Nipah virus, SARS CoV

Collaboration Opportunities

- Phage-displayed antibody library from 10 healthy humans
- Phage-displayed antibody library from 50 humans
- Collaborations for development of novel human antibodies targeting DR4, DR5, Mesothelin, CD22, Her2, EphrinB2 and other cancer-related proteins

Contact Information

Dimiter S Dimitrov, PhD ScD
Senior Investigator
Protein Interactions, CCRNP, CCR, NCI-Frederick, NIH
Bldg 469, Rm 150B
P.O. Box B, Miller Drive
Frederick, MD 21702-1201

phone: 301-846-1352
FAX: 301-846-5598
e-mail: dimitrov@ncifcrf.gov
Web site http://www-lecb.ncifcrf.gov/~dimitrov/dimitrov.html